Systematic optimization for production of the anti-MRSA antibiotics WAP-8294A in an engineered strain of Lysobacter enzymogenes

Xusheng Chen, Shanren Li, Lingjun Yu, Amanda Miller, Liangcheng Du

Research output: Contribution to journalArticle

Abstract

WAP-8294A is a group of cyclic lipodepsipeptides and considered as the first-in-class new chemical entity with potent activity against methicillin-resistant Staphylococcus aureus. One of the roadblocks in developing the WAP-8294A antibiotics is the very low yield in Lysobacter. Here, we carried out a systematic investigation of the nutritional and environmental conditions in an engineered L. enzymogenes strain for the optimal production of WAP-8294A. We developed an activity-based simple method for quick screening of various factors, which enabled us to optimize the culture conditions. With the method, we were able to improve the WAP-8294A yield by 10-fold in small-scale cultures and approximately 15-fold in scale-up fermentation. Additionally, we found the ratio of WAP-8294A2 to WAP-8294A1 in the strains could be manipulated through medium optimization. The development of a practical method for yield improvement in Lysobacter will facilitate the ongoing basic research and clinical studies to develop WAP-8294A into true therapeutics.

Original languageEnglish (US)
Pages (from-to)1430-1440
Number of pages11
JournalMicrobial Biotechnology
Volume12
Issue number6
DOIs
StatePublished - Nov 1 2019

Fingerprint

Lysobacter
Antibiotics
Methicillin-Resistant Staphylococcus aureus
Anti-Bacterial Agents
Methicillin
Fermentation
Screening
Research
Therapeutics

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biochemistry
  • Applied Microbiology and Biotechnology

Cite this

Systematic optimization for production of the anti-MRSA antibiotics WAP-8294A in an engineered strain of Lysobacter enzymogenes. / Chen, Xusheng; Li, Shanren; Yu, Lingjun; Miller, Amanda; Du, Liangcheng.

In: Microbial Biotechnology, Vol. 12, No. 6, 01.11.2019, p. 1430-1440.

Research output: Contribution to journalArticle

@article{9982caabc5ec4224a3986af74df20fd5,
title = "Systematic optimization for production of the anti-MRSA antibiotics WAP-8294A in an engineered strain of Lysobacter enzymogenes",
abstract = "WAP-8294A is a group of cyclic lipodepsipeptides and considered as the first-in-class new chemical entity with potent activity against methicillin-resistant Staphylococcus aureus. One of the roadblocks in developing the WAP-8294A antibiotics is the very low yield in Lysobacter. Here, we carried out a systematic investigation of the nutritional and environmental conditions in an engineered L. enzymogenes strain for the optimal production of WAP-8294A. We developed an activity-based simple method for quick screening of various factors, which enabled us to optimize the culture conditions. With the method, we were able to improve the WAP-8294A yield by 10-fold in small-scale cultures and approximately 15-fold in scale-up fermentation. Additionally, we found the ratio of WAP-8294A2 to WAP-8294A1 in the strains could be manipulated through medium optimization. The development of a practical method for yield improvement in Lysobacter will facilitate the ongoing basic research and clinical studies to develop WAP-8294A into true therapeutics.",
author = "Xusheng Chen and Shanren Li and Lingjun Yu and Amanda Miller and Liangcheng Du",
year = "2019",
month = "11",
day = "1",
doi = "10.1111/1751-7915.13484",
language = "English (US)",
volume = "12",
pages = "1430--1440",
journal = "Microbial Biotechnology",
issn = "1751-7907",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Systematic optimization for production of the anti-MRSA antibiotics WAP-8294A in an engineered strain of Lysobacter enzymogenes

AU - Chen, Xusheng

AU - Li, Shanren

AU - Yu, Lingjun

AU - Miller, Amanda

AU - Du, Liangcheng

PY - 2019/11/1

Y1 - 2019/11/1

N2 - WAP-8294A is a group of cyclic lipodepsipeptides and considered as the first-in-class new chemical entity with potent activity against methicillin-resistant Staphylococcus aureus. One of the roadblocks in developing the WAP-8294A antibiotics is the very low yield in Lysobacter. Here, we carried out a systematic investigation of the nutritional and environmental conditions in an engineered L. enzymogenes strain for the optimal production of WAP-8294A. We developed an activity-based simple method for quick screening of various factors, which enabled us to optimize the culture conditions. With the method, we were able to improve the WAP-8294A yield by 10-fold in small-scale cultures and approximately 15-fold in scale-up fermentation. Additionally, we found the ratio of WAP-8294A2 to WAP-8294A1 in the strains could be manipulated through medium optimization. The development of a practical method for yield improvement in Lysobacter will facilitate the ongoing basic research and clinical studies to develop WAP-8294A into true therapeutics.

AB - WAP-8294A is a group of cyclic lipodepsipeptides and considered as the first-in-class new chemical entity with potent activity against methicillin-resistant Staphylococcus aureus. One of the roadblocks in developing the WAP-8294A antibiotics is the very low yield in Lysobacter. Here, we carried out a systematic investigation of the nutritional and environmental conditions in an engineered L. enzymogenes strain for the optimal production of WAP-8294A. We developed an activity-based simple method for quick screening of various factors, which enabled us to optimize the culture conditions. With the method, we were able to improve the WAP-8294A yield by 10-fold in small-scale cultures and approximately 15-fold in scale-up fermentation. Additionally, we found the ratio of WAP-8294A2 to WAP-8294A1 in the strains could be manipulated through medium optimization. The development of a practical method for yield improvement in Lysobacter will facilitate the ongoing basic research and clinical studies to develop WAP-8294A into true therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85073592721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073592721&partnerID=8YFLogxK

U2 - 10.1111/1751-7915.13484

DO - 10.1111/1751-7915.13484

M3 - Article

C2 - 31520522

AN - SCOPUS:85073592721

VL - 12

SP - 1430

EP - 1440

JO - Microbial Biotechnology

JF - Microbial Biotechnology

SN - 1751-7907

IS - 6

ER -